 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning ImmunoGen, Inc.
|
-
ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds
(08 Jan 2008)
Company to Develop TAP Compound to Novel Target Using Centocor Antibody
ImmunoGen, Inc. announced that it has licensed the exclusive right to develop and commercialize a TAP compound to a novel target using an antibody created by Centocor. This license supersedes the previous agreement between the companies.Under the ...
-
ImmunoGen, Inc. Achieves Milestone in Tumor Antibody Collaboration with Genentech
(02 Feb 2006)
Trastuzumab-DM1 IND Becomes Effective
ImmunoGen, Inc. announced that the Company has been informed by Genentech that the trastuzumab-DM1 Investigational New Drug (IND) application submitted by Genentech to the U.S. Food and Drug Administration (FDA) has become effective. This event ...
-
ImmunoGen, Inc. Announces that the sanofi-aventis Group Has Extended its Research Collaboration with the Company
(02 Sep 2005)
ImmunoGen, Inc. announced that Aventis Pharmaceuticals Inc. of the sanofi-aventis Group has exercised its right to extend the term of its research collaboration with the Company and committed to fund ImmunoGen $18.2 million in research support over ...
-
MorphoSys Grants ImmunoGen Access to HuCAL GOLDŽ
(02 Jun 2005)
MorphoSys AG announced that the US biotechnology company, ImmunoGen Inc., has licensed access to the MorphoSys HuCAL GOLDŽ library for use in ImmunoGen's internal target research programs. ImmunoGen will pay MorphoSys subscription fees during the ...
-
ImmunoGen, Inc. Announces Genentech's Renewal of Technology Access Agreement
(09 May 2005)
ImmunoGen, Inc. announced that Genentech has renewed the agreement that provides Genentech with certain rights to test and to use ImmunoGen's Tumor-Activated Prodrug (TAP) technology with Genentech therapeutic antibodies to specific targets. The ...
-
ImmunoGen and Millennium Sign Exclusive Product License
(21 Feb 2002)
ImmunoGen, Inc. today announced that the Company and Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) have signed an exclusive product license for use of ImmunoGen's proprietary maytansinoid Tumor-Activated Prodrug (TAP) technology with Millennium's ...
-
ImmunoGen, Inc. Receives Patent on Production of DM1
(07 Jan 2002)
ImmunoGen, Inc. today announced that the U.S. Patent and Trademark Office has issued the Company U.S. Patent 6,333,410 B1, which covers the preparation and purification of thiol-containing maytansinoids, such as DM1. DM1 is the lead small molecule ...
Additional information
ImmunoGen, Inc.
Cambridge, MA, USA
Company
|
|
|
|
|
|
Top
